Weekly treatment with SAMiRNA targeting the androgen receptor ameliorates androgenetic alopecia

    January 2022 in “Scientific Reports
    Sun-Gil Yun, Sang Yup Lee, Eun-Ah Goh, Oh-Seung Kwon, Woorim Choi, Jong-Choon Kim, Mi-Sun Lee, Soon-Mok Choi, Baojun Xu, Tae Wha Moon, Sin Gon Kim, Keeyeol Kyong, Gaewon Nam, Han Oh Park
    Image of study
    TLDR A new treatment called SAMiRNA-AR68 increases hair count in people with hair loss, showing similar results to existing treatments but without side effects.
    The document discusses two clinical trials investigating SAMiRNA-AR68, a new treatment for androgenetic alopecia (AGA). The first trial involved 45 subjects treated with a low dose of AR68 (0.5 mg/ml) three times per week for 24 weeks, resulting in an increase in total hair count from 133.14 to 135.41 hairs/cm2. The second trial involved 43 subjects treated with a high dose of AR68 (5 mg/ml) once per week for 24 weeks, leading to a significant increase in total hair count from 182.182 to 189.909 hairs/cm2. The high-dose treatment showed approximately 240% efficacy compared to the low-dose group. One subject in the high-dose group experienced an adverse reaction, but it was not caused by the test substance. The study concluded that SAMiRNA-AR68 is a promising new treatment for AGA, with comparable efficacy to finasteride but without side effects.
    View this study on nature.com →

    Cited in this study

    Related